

SUPPORT FOR THE AMENDMENT

Support for new claims 63-78 is found on pages 2-18 of the specification and in the original claims.

REMARKS

Claims 21-78 are presented for initial examination.

The claims have been amended to eliminate all multiple dependencies (Claims 23, 28, 31-34, 41, 44-45, 52, 55-56, 58, 60 and 62) and to provide conventional Markush language (Claim 34). No new matter is believed to be added to the application by entry of these amendments. None of the amendments to the claims are believed to be a narrowing of the claims and, accordingly, should not limit interpretation of the claims under the Doctrine of Equivalents.

A written paper copy of the Sequence Listing and a computer readable form of the Sequence Listing are provided herewith in accordance with 37 C.F.R. §1.821-1.825. The Sequence Listing information recorded in computer readable form is believed to be identical to the written Sequence

DELANSORNE ET AL. PCT/EP/99/07389

01056

Listing. Submission of the Sequence Listing does not include new matter.

Applicants also submit herewith a copy of the Search Report from the European Patent Office, together with copies of the references cited therein, which are listed on the attached Form PTO-1449.

Respectfully submitted,



Ira J. Schultz
Registration No. 28,666

LAW OFFICES
DENNISON, SCHEINER, SCHULTZ & WAKEMAN
612 CRYSTAL SQUARE 4
1745 JEFFERSON DAVIS HIGHWAY
ARLINGTON, VIRGINIA 22202-3417
703 412-1155

MARKED UP COPY OF AMENDED CLAIMS

Claims 1-20 have been canceled.

--23. (Amended) The pharmaceutical composition according to claim 21 [**or 22**] wherein said peptide analogue has the formula (SEQ ID N° : 1) :

A1-A2-A3-A4-A5-A6-A7-A8-Pro-Z (A)

in which :

- A1 is pGlu ; D-pGlu ; Sar ; AcSar ; Pro or a derivative thereof ; Ser ; D-Ser ; Ac-D-Ser ; Thr ; D-Thr ; Ac-D-Thr ; or an aromatic D-amino acid which may be acylated ;
- A2 is a direct bond ; His ; or an aromatic D-amino acid;
- A3 is an aromatic L- or D-amino acid;
- A4 is Ala, Ser, D-Ser, MeSer, Ser(OBu^t), Ser(OBzl) or Thr;
- A5 is an aromatic L-amino acid ; or a basic L- or D-amino acid;
- A6 is Gly ; (S)-spirolactam-Pro ; D-Pro ; D-Ser ; D-Thr ; D-Cys ; D-Met ; D-Pen ; D-(S-Me) Pen ; D-(S-Et) Pen ; D-Ser(OBu^t) ; D-Asp(OBu^t) ; D-Glu(OBu^t) ; D-Thr(OBu^t) ; D-Cys(OBu^t) ; D-Ser(OR₁) where R₁ is a sugar moiety ; an aza-amino acid ; D-His which may be substituted on the imidazole ring by a (C₁-C₆) alkyl, a (C₂-C₇) acyl or a benzyl group ; an aliphatic D-

amino acid with a (C_1-C_8)alkyl or a (C_3-C_6)cycloalkyl side chain ; an aromatic D-amino acid ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ; D-perhydrodiphenyl-Ala ; or a basic L- or D-amino acid;

- A7 is a linear, branched or cyclic aliphatic L-amino acid of 3 to 20 carbon atoms which may be N-alpha-substituted by a (C_1-C_4)alkyl group optionally substituted by one or several fluorine atoms;

- A8 is a basic L- or D-amino acid ;

- Z is GlyNH₂ ; D-AlaNH₂ ; azaGlyNH₂ ; or a group -NHR₂ where R₂ is a (C_1-C_4)alkyl which may be substituted by an hydroxy or one or several fluorine atoms ; a (C_3-C_6)cycloalkyl ; or a heterocyclic radical selected from morpholinyl, pyrrolidinyl and piperidyl.

28. (Amended) The pharmaceutical composition according to [one of claims 24 to 27] claim 24 wherein the peptide analogue is selected from the group consisting of leuprorelin, [Npg⁷]-leuprorelin, triptorelin, [Npg⁷]-triptorelin, goserelin, [Npg⁷]-goserelin, buserelin and [Npg⁷]-buserelin.

31. (Amended) The pharmaceutical composition according to claim 29 [or 30] wherein the peptide analogue is selected from

the group consisting of antide, [Npg⁷]-antide, cetrorelix, [Npg⁷]-cetrorelix, abarelix and [Npg⁷]-abarelix.

32. (Amended) The pharmaceutical composition according to [one of claims 21 to 31] claim 21 wherein the α-cyclodextrin derivative is selected from the group consisting of methylated α-cyclodextrin, hexakis(2,3,6-tri-O-methyl)-α-cyclodextrin, carboxy-methylated α-cyclodextrin and phosphated α-cyclodextrin.

33. (Amended) The pharmaceutical composition according to [claims 21 to 32] claim 21 wherein the α-cyclodextrin derivative is hexakis(2,3,6-tri-O-methyl)-α-cyclodextrin in combination with the LH-RH peptide analogue.

34. (Amended) The pharmaceutical composition according to [one of claims 21 to 33] claim 21 which further comprises a compound selected from the group consisting of a protease inhibitor [and/or], an absorption enhancer, and mixtures thereof.

41. (Amended) The method according to [one of claims 37 to 40] claim 37 wherein the peptide analogue is selected from the group consisting of leuprorelin, [Npg⁷]-leuprorelin,

triptorelin, [Npg⁷]-triptorelin, goserelin, [Npg⁷]-goserelin, buserelin and [Npg⁷]-buserelin.

44. (Amended) The method according to claim 42 **[or 43]** wherein the peptide analogue is selected from the group consisting of antide, [Npg⁷]-antide, cetrorelix, [Npg⁷]-cetrorelix, abarelix and [Npg⁷]-abarelix.

45. (Amended) The method according to **[one of claims 35 to 44] claim 35** wherein the α -cyclodextrin derivative is selected from the group consisting of methylated α -cyclodextrin, hexakis(2,3,6-tri-O-methyl)- α -cyclodextrin, carboxymethylated α -cyclodextrin and phosphated α -cyclodextrin.

52. (Amended) The method according to **[one of claims 48 to 51] claim 48** wherein the peptide analogue is selected from the group consisting of leuprorelin, [Npg⁷]-leuprorelin, triptorelin, [Npg⁷]-triptorelin, goserelin, [Npg⁷]-goserelin, buserelin and [Npg⁷]-buserelin.

55. (Amended) The method according to claim 53 **[or 54]** wherein the peptide analogue is selected from the group consisting of antide, [Npg⁷]-antide, cetrorelix, [Npg⁷]-cetrorelix, abarelix and [Npg⁷]-abarelix.

56. (Amended) The method according to [one of claims 47 to 55] claim 47 wherein the α -cyclodextrin derivative is selected from the group consisting of methylated α -cyclodextrin, hexakis(2,3,6-tri-O-methyl)- α -cyclodextrin, carboxymethylated α -cyclodextrin and phosphated α -cyclodextrin.

58. (Amended) The method according to [one of claims 47 to 57] claim 47 for the treatment or prevention of breast cancer.

60. (Amended). The method according to [one of claims 47 to 57] claim 47 for the treatment or prevention of prostate cancer or benign prostatic hypertrophy.

62. (Amended) The method according to [one of claims 47 to 61] claim 47 wherein the peptide analogue is delivered to the gastrointestinal tract of the patient.

Claims 63-78 were added.